Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
鼠抗人T淋巴细胞CD3表面抗原单克隆抗体注射液II期临床试验
[Translation] Phase II clinical trial of mouse anti-human T lymphocyte CD3 surface antigen monoclonal antibody injection
评价鼠抗人T淋巴细胞CD3表面抗原单克隆抗体注射液治疗再生障碍性贫血(慢性型)的疗效和安全性
[Translation] To evaluate the efficacy and safety of mouse anti-human T lymphocyte CD3 surface antigen monoclonal antibody injection in the treatment of aplastic anemia (chronic type)
注射用鼠抗人T淋巴细胞CD3表面抗原单克隆抗体I期临床试验
[Translation] Phase I clinical trial of mouse anti-human T lymphocyte CD3 surface antigen monoclonal antibody for injection
观察人体对注射用鼠抗人T淋巴细胞CD3表面抗原单克隆抗体的耐受性,为制定II期临床试验的给药方案提供依据
[Translation] To observe the human body's tolerance to the mouse anti-human T lymphocyte CD3 surface antigen monoclonal antibody for injection, and provide a basis for formulating the dosing regimen for Phase II clinical trials
100 Clinical Results associated with Jinan Tiankang Biological Products Co., Ltd.
0 Patents (Medical) associated with Jinan Tiankang Biological Products Co., Ltd.
100 Deals associated with Jinan Tiankang Biological Products Co., Ltd.
100 Translational Medicine associated with Jinan Tiankang Biological Products Co., Ltd.